
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1873025/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. New England Journal of Medicine, 2002, 347, 975-982.	13.9	6,268
2	Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C. New England Journal of Medicine, 1998, 339, 1485-1492.	13.9	3,341
3	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	1.8	2,171
4	Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120, 1183-1192.	0.6	1,846
5	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	0.6	1,840
6	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	13.9	1,548
7	Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. New England Journal of Medicine, 2009, 361, 580-593.	13.9	1,166
8	Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 2003, 37, 1286-1292.	3.6	984
9	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. New England Journal of Medicine, 2015, 373, 2608-2617.	13.9	740
10	Genetics and epigenetics of NAFLD and NASH: Clinical impact. Journal of Hepatology, 2018, 68, 268-279.	1.8	670
11	Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. Gastroenterology, 2010, 139, 120-129.e18.	0.6	633
12	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology, 2008, 48, 792-798.	3.6	600
13	A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology, 2001, 34, 395-403.	3.6	585
14	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2010, 51, 1209-1217.	3.6	563
15	Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3. New England Journal of Medicine, 2007, 357, 124-134.	13.9	523
16	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016, 150, 1219-1230.e6.	0.6	506
17	Nuclear Trapping of the Forkhead Transcription Factor FoxO1 via Sirt-dependent Deacetylation Promotes Expression of Glucogenetic Genes. Journal of Biological Chemistry, 2005, 280, 20589-20595.	1.6	459
18	Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology, 2006, 43, 682-689.	3.6	458

#	Article	IF	CITATIONS
19	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology, 2015, 61, 506-514.	3.6	424
20	A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology, 2004, 2, 1107-1115.	2.4	388
21	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
22	Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology, 2015, 63, 705-712.	1.8	309
23	PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Human Molecular Genetics, 2014, 23, 4077-4085.	1.4	293
24	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLARÂtrials. Journal of Hepatology, 2020, 73, 26-39.	1.8	290
25	Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology, 2002, 122, 274-280.	0.6	285
26	A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology, 2007, 46, 297-306.	3.6	285
27	Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. Journal of Hepatology, 2011, 55, 920-932.	1.8	279
28	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohorta ~†. Journal of Hepatology, 2020, 73, 505-515.	1.8	279
29	Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study. American Journal of Gastroenterology, 2007, 102, 1251-1258.	0.2	274
30	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. Journal of Internal Medicine, 2018, 283, 356-370.	2.7	256
31	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease, 2017, 49, 471-483.	0.4	254
32	1148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology, 2010, 52, 1274-1280.	3.6	252
33	COVIDâ€19 and liver disease. Liver International, 2020, 40, 1278-1281.	1.9	252
34	HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2010, 138, 905-912.	0.6	246
35	Update on NAFLD genetics: From new variants to the clinic. Journal of Hepatology, 2020, 72, 1196-1209.	1.8	234
36	Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology, 2011, 53, 791-799.	3.6	227

#	Article	IF	CITATIONS
37	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology, 2019, 70, 1913-1927.	3.6	226
38	A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology, 1995, 22, 759-766.	3.6	209
39	Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. American Journal of Gastroenterology, 2001, 96, 2448-2455.	0.2	207
40	PNPLA3 I148M polymorphism and progressive liver disease. World Journal of Gastroenterology, 2013, 19, 6969.	1.4	207
41	Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology, 2007, 46, 371-379.	3.6	203
42	Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. Gastroenterology, 2007, 132, 103-112.	0.6	200
43	NAFLD in children: new genes, new diagnostic modalities and new drugs. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 517-530.	8.2	199
44	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology, 2019, 70, 1521-1530.	3.6	197
45	Association between the <i>PNPLA3</i> (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology, 2014, 59, 2170-2177.	3.6	193
46	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports, 2017, 7, 4492.	1.6	193
47	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. Journal of Hepatology, 2021, 74, 775-782.	1.8	193
48	Carotid Artery Intima-media Thickness in Nonalcoholic Fatty Liver Disease. American Journal of Medicine, 2008, 121, 72-78.	0.6	189
49	Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment. Current Pharmaceutical Design, 2013, 19, 5219-5238.	0.9	184
50	Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis. Diabetes, 2008, 57, 1355-1362.	0.3	163
51	Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Journal of Hepatology, 2011, 55, 69-75.	1.8	160
52	Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporosis International, 2009, 20, 549-555.	1.3	158
53	The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the national digestive diseases advisory board. Hepatology, 1995, 22, 1591-1597.	3.6	157
54	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology, 2012, 56, 448-454.	1.8	156

#	Article	IF	CITATIONS
55	A 360-degree overview of paediatric NAFLD: Recent insights. Journal of Hepatology, 2013, 58, 1218-1229.	1.8	154
56	Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Science Translational Medicine, 2018, 10, .	5.8	151
57	Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology, 2010, 51, 388-397.	3.6	149
58	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2014, 61, 148-154.	1.8	149
59	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology, 2021, 75, 770-785.	1.8	149
60	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut, 2010, 59, 267-273.	6.1	148
61	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clinical Gastroenterology and Hepatology, 2017, 15, 1604-1611.e1.	2.4	146
62	Iron Depletion by Deferoxamine Up-Regulates Glucose Uptake and Insulin Signaling in Hepatoma Cells and in Rat Liver. American Journal of Pathology, 2008, 172, 738-747.	1.9	144
63	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 406-421.e7.	7.2	141
64	Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Molecular Metabolism, 2019, 22, 49-61.	3.0	140
65	Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transplantation, 2004, 10, 1248-1255.	1.3	136
66	Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology and Hepatology, 2022, 7, 388-390.	3.7	135
67	Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. Cell Metabolism, 2020, 31, 35-45.	7.2	130
68	Dietary Iron Overload Induces Visceral Adipose Tissue Insulin Resistance. American Journal of Pathology, 2013, 182, 2254-2263.	1.9	128
69	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity, 2021, 116, 102560.	3.0	127
70	Pathophysiology of Non Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2016, 17, 2082.	1.8	126
71	Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. Liver International, 2016, 36, 1563-1579.	1.9	126
72	Liver fat accumulation is associated with circulating PCSK9. Annals of Medicine, 2016, 48, 384-391.	1.5	119

#	Article	IF	CITATIONS
73	Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 969-986.e7.	7.2	117
74	Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World Journal of Gastroenterology, 2014, 20, 12945.	1.4	117
75	Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. BioMed Research International, 2015, 2015, 1-10.	0.9	116
76	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. Gut, 2022, 71, 382-390.	6.1	113
77	Nonalcoholic Fatty Liver Disease in Children. Seminars in Liver Disease, 2018, 38, 001-013.	1.8	108
78	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Journal of Hepatology, 2011, 54, 1244-1249.	1.8	107
79	A population-based study on the prevalence of NASH using scores validated against liver histology. Journal of Hepatology, 2014, 60, 839-846.	1.8	107
80	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 682-690.	1.8	106
81	The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology, 2007, 46, 1091-1100.	3.6	104
82	Nutritional therapy for nonalcoholic fatty liver disease. Journal of Nutritional Biochemistry, 2016, 29, 1-11.	1.9	100
83	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2021, 75, 786-794.	1.8	100
84	Dietary Anthocyanins as Nutritional Therapy for Nonalcoholic Fatty Liver Disease. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-8.	1.9	98
85	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. Journal of Hepatology, 2018, 69, 18-24.	1.8	98
86	The rs2294918 E434K variant modulates patatinâ€like phospholipase domainâ€containing 3 expression and liver damage. Hepatology, 2016, 63, 787-798.	3.6	93
87	The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?. Seminars in Immunopathology, 2009, 31, 359-369.	2.8	89
88	Tumor necrosis factor α promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood, 2001, 97, 3707-3712.	0.6	88
89	α1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage. Hepatology, 2006, 44, 857-864.	3.6	88
90	PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Human Molecular Genetics, 2016, 25, ddw341.	1.4	86

#	Article	IF	CITATIONS
91	LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. Gut, 2021, 70, 180-193.	6.1	86
92	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	1.6	85
93	A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World Journal of Gastroenterology, 2014, 20, 3002.	1.4	85
94	Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Digestive and Liver Disease, 2003, 35, 172-178.	0.4	84
95	Genetics of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1026-1037.	1.5	84
96	DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. Clinical Epigenetics, 2015, 7, 61.	1.8	83
97	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Scientific Reports, 2019, 9, 11585.	1.6	82
98	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. Gastroenterology, 2021, 160, 1634-1646.e7.	0.6	82
99	The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. Journal of Medical Genetics, 2004, 41, 946-950.	1.5	81
100	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology, 2012, 55, 336-342.	3.6	81
101	Iron and insulin resistance. Alimentary Pharmacology and Therapeutics, 2005, 22, 61-63.	1.9	80
102	Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection. Annals of Internal Medicine, 2015, 163, 809-817.	2.0	79
103	Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 568-575.	1.1	78
104	Serum Hepcidin and Macrophage Iron Correlate With MCP-1 Release and Vascular Damage in Patients With Metabolic Syndrome Alterations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 683-690.	1.1	78
105	Hepatic Notch Signaling Correlates With Insulin Resistance and Nonalcoholic Fatty Liver Disease. Diabetes, 2013, 62, 4052-4062.	0.3	78
106	PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity ,. Journal of Nutrition, 2015, 145, 1687-1691.	1.3	78
107	Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10Âyears of follow-up. Atherosclerosis, 2016, 246, 208-213.	0.4	78
108	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology, 2021, 74, 20-30.	1.8	77

#	Article	IF	CITATIONS
109	Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2004, 36, 333-336.	0.4	76
110	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. Hepatology, 2020, 72, 88-102.	3.6	76
111	Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology, 2017, 66, 1885-1893.	3.6	75
112	Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology. Hepatology, 2020, 72, 330-346.	3.6	75
113	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut, 2020, 69, 1855-1866.	6.1	75
114	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. Journal of Hepatology, 2011, 55, 1409-1414.	1.8	74
115	A 4â€Polymorphism Risk Score Predicts Steatohepatitis in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 632-636.	0.9	74
116	Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels. Clinical Gastroenterology and Hepatology, 2006, 4, 645-652.	2.4	73
117	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. Journal of Clinical Investigation, 2021, 131, .	3.9	72
118	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials, 2020, 98, 106175.	0.8	71
119	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine, 2020, 52, 102658.	2.7	71
120	Beyond hereditary hemochromatosis: New insights into the relationship between iron overload and chronic liver diseases. Digestive and Liver Disease, 2011, 43, 89-95.	0.4	69
121	Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology, 2013, 58, 1245-1252.	3.6	69
122	Iron-Dependent Regulation of MDM2 Influences p53 Activity and Hepatic Carcinogenesis. American Journal of Pathology, 2010, 176, 1006-1017.	1.9	68
123	Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis, 2019, 282, 110-120.	0.4	68
124	SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. Blood Transfusion, 2021, 19, 181-189.	0.3	68
125	Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology, 1994, 19, 933-940.	3.6	66
126	Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica, 2007, 92, 1037-1042.	1.7	66

#	Article	IF	CITATIONS
127	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2310-2319.e6.	2.4	66
128	Hepatic iron is the major determinant of serum ferritin in <scp>NAFLD</scp> patients. Liver International, 2018, 38, 164-173.	1.9	65
129	Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling–a propensity score-adjusted observational study. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 141-149.	0.2	64
130	Paradoxical Dissociation Between Hepatic Fat Content and De Novo Lipogenesis Due to PNPLA3 Sequence Variant. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E821-E825.	1.8	64
131	Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Clinical Science, 2017, 131, 1301-1315.	1.8	64
132	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0163069.	1.1	63
133	The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterology, 2012, 12, 111.	0.8	62
134	Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2010, 53, 927-933.	1.8	60
135	The I148M Variant of PNPLA3 Reduces the Response to Docosahexaenoic Acid in Children with Non-Alcoholic Fatty Liver Disease. Journal of Medicinal Food, 2013, 16, 957-960.	0.8	60
136	Red cell–bound antibodies and transfusion requirements in hospitalized patients with COVID-19. Blood, 2020, 136, 766-768.	0.6	60
137	<i>LPIN1</i> rs13412852 Polymorphism in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 588-593.	0.9	59
138	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2013, 8, e74089.	1.1	59
139	TNF alpha polymorphisms, HFE gene mutations and acquired factors in Italian patients with porphyria cutanea tarda. Journal of Hepatology, 2002, 36, 157-158.	1.8	58
140	Plasma Chromogranin A Response to Octreotide Test: Prognostic Value for Clinical Outcome in Endocrine Digestive Tumors. American Journal of Gastroenterology, 2010, 105, 2072-2078.	0.2	57
141	Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. Genes and Nutrition, 2014, 9, 392.	1.2	56
142	A "systems medicine―approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, 333-342.	0.4	56
143	PNPLA3 I148M variant and hepatocellular carcinoma: A common genetic variant for a rare disease. Digestive and Liver Disease, 2013, 45, 619-624.	0.4	55
144	A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. Clinical Gastroenterology and Hepatology, 2022, 20, 658-673.	2.4	55

#	Article	IF	CITATIONS
145	Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Seminars in Liver Disease, 2021, 41, 421-434.	1.8	55
146	A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2017, 18, 1534.	1.8	54
147	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology, 2010, 10, 102.	0.8	53
148	Relationship between TNF-α and iron metabolism in differentiating human monocytic THP-1 cells. British Journal of Haematology, 2000, 110, 978-984.	1.2	52
149	Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. International Journal of Molecular Medicine, 2012, 30, 49-56.	1.8	52
150	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology, 2015, 62, 111-117.	3.6	52
151	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. DMM Disease Models and Mechanisms, 2015, 8, 1037-46.	1.2	52
152	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. Journal of Hepatology, 2018, 69, 1365-1370.	1.8	51
153	Serum coding and nonâ€coding RNAs as biomarkers of NAFLD and fibrosis severity. Liver International, 2019, 39, 1742-1754.	1.9	51
154	Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e41183.	1.1	51
155	Treatment of Chronic Hepatitis C Virus in African Americans With Genotypes 2 and 3. CME. American Journal of Gastroenterology, 2007, 102, 761-766.	0.2	50
156	Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. Journal of Hepatology, 2010, 52, 832-838.	1.8	50
157	<i>Patatin-like phospholipase domain containing-3</i> gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World Journal of Gastroenterology, 2012, 18, 2813.	1.4	50
158	Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. Science Translational Medicine, 2021, 13, .	5.8	49
159	Telomeres, NAFLD and Chronic Liver Disease. International Journal of Molecular Sciences, 2016, 17, 383.	1.8	48
160	β-Klotho gene variation is associated with liver damage in children with NAFLD. Journal of Hepatology, 2020, 72, 411-419.	1.8	48
161	Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. Hepatology, 2020, 72, 1912-1923.	3.6	48
162	High Fat Diet Subverts Hepatocellular Iron Uptake Determining Dysmetabolic Iron Overload. PLoS ONE, 2015, 10, e0116855.	1.1	47

#	Article	IF	CITATIONS
163	Circulating ghrelin levels in patients with inflammatory bowel disease. Gut, 2006, 55, 432-433.	6.1	46
164	Glucagon-Like Peptide 1 Inhibits the Sirtuin Deacetylase SirT1 to Stimulate Pancreatic β-Cell Mass Expansion. Diabetes, 2011, 60, 3217-3222.	0.3	46
165	The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2018, 22, 109-119.	1.0	46
166	The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 229-242.	1.4	44
167	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An ageâ€dependent risk profiling study. Liver International, 2017, 37, 1389-1396.	1.9	44
168	Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. Journal of Autoimmunity, 2021, 117, 102595.	3.0	44
169	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in InÂVitro Models. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 759-788.	2.3	44
170	Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. Journal of Hepatology, 2006, 44, 679-685.	1.8	43
171	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Medicine, 2017, 6, 1930-1940.	1.3	43
172	Redefining fatty liver disease classification in 2020. Liver International, 2020, 40, 1016-1017.	1.9	43
173	Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2012, 18, 3782.	1.4	43
174	The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e48804.	1.1	42
175	Fibronectin Type III Domain–Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2660-2669.	1.8	42
176	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of Lipid Research, 2019, 60, 1144-1153.	2.0	42
177	PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e75982.	1.1	42
178	The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. Journal of Rheumatology, 2008, 35, 153-8.	1.0	42
179	Hemochromatosis gene (HFE) mutations and cancer risk: Expanding the clinical manifestations of hereditary iron overload. Hepatology, 2010, 51, 1119-1121.	3.6	41
180	The <i><scp>UCP</scp>2</i> â€866ÂG>A promoter region polymorphism is associated with nonalcoholic steatohepatitis Liver International, 2015, 35, 1574-1580.	1.9	41

#	Article	IF	CITATIONS
181	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0162473.	1.1	41
182	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. Journal of Hepatology, 2021, 75, 506-513.	1.8	40
183	Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology, 2003, 124, 866.	0.6	38
184	A Promoter Polymorphism in the Liver-specific Fatty Acid Transport Protein 5 is Associated with Features of the Metabolic Syndrome and Steatosis. Hormone and Metabolic Research, 2010, 42, 854-859.	0.7	38
185	Long term changes in liver histology following treatment of chronic hepatitis C virus. Annals of Hepatology, 2014, 13, 340-349.	0.6	38
186	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. Hepatology Communications, 2018, 2, 666-675.	2.0	38
187	Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. Metabolism: Clinical and Experimental, 2019, 96, 56-65.	1.5	38
188	Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease. Liver International, 2019, 39, 250-256.	1.9	38
189	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. Journal of Hepatology, 2020, 73, 593-602.	1.8	38
190	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. Journal of Hepatology, 2022, 77, 596-606.	1.8	38
191	Novel genes and sex differences in COVID-19 severity. Human Molecular Genetics, 2022, 31, 3789-3806.	1.4	38
192	Unraveling the genetics of fatty liver in obese children: Additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology, 2012, 55, 661-663.	3.6	37
193	Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. International Journal of Obesity, 2013, 37, 986-992.	1.6	37
194	Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning. European Journal of Preventive Cardiology, 2020, 27, 1639-1646.	0.8	37
195	Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. Hepatology Communications, 2021, 5, 1824-1832.	2.0	37
196	Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. Journal of Hepatology, 2011, 55, 647-653.	1.8	36
197	Hepcidin resistance in dysmetabolic iron overload. Liver International, 2016, 36, 1540-1548.	1.9	36
198	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. Diabetes and Metabolism, 2019, 45, 480-487.	1.4	36

#	Article	IF	CITATIONS
199	TNFα genotype affects TNFα release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. Journal of Hepatology, 2005, 43, 944-950.	1.8	35
200	Hemochromatosis in Italy in the last 30 years: Role of genetic and acquired factors. Hepatology, 2010, 51, 501-510.	3.6	35
201	Implications of <i><scp>PNPLA</scp>3</i> polymorphism in chronic hepatitis <scp>C</scp> patients receiving peginterferon plus ribavirin. Alimentary Pharmacology and Therapeutics, 2012, 35, 1434-1442.	1.9	35
202	Retreatment of patients with chronic hepatitis C. Hepatology, 2002, 36, S128-S134.	3.6	34
203	Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. Digestive and Liver Disease, 2019, 51, 1586-1592.	0.4	34
204	MAFLD vs NAFLD: Let the contest begin!. Liver International, 2020, 40, 2079-2081.	1.9	34
205	COVIDâ€19 and the liver: A 2021 update. Liver International, 2021, 41, 1988-1998.	1.9	34
206	Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. Journal of Hepatology, 2012, 57, 1319-1325.	1.8	33
207	<i>PNPLA3</i> 1148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. Liver International, 2020, 40, 1130-1141.	1.9	33
208	Red blood cell morphology in patients with COVID-19-related anaemia. Blood Transfusion, 2021, 19, 34-36.	0.3	33
209	Retreatment of patients with chronic hepatitis C. Hepatology, 2002, 36, s128-s134.	3.6	32
210	AISF position paper on liver disease and pregnancy. Digestive and Liver Disease, 2016, 48, 120-137.	0.4	32
211	Association of <scp>ABO</scp> blood group and secretor phenotype with severe <scp>COVID</scp> â€19. Transfusion, 2020, 60, 3067-3070.	0.8	32
212	Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology, 2009, 137, 1986-1994.	0.6	31
213	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology, 2016, 63, 418-427.	3.6	31
214	Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia. Journal of Clinical Lipidology, 2016, 10, 816-823.	0.6	31
215	Prognostic parameters of inâ€hospital mortality in COVIDâ€19 patients—An Italian experience. European Journal of Clinical Investigation, 2021, 51, e13629.	1.7	31
216	Risk of Obstructive Sleep Apnea with Daytime Sleepiness Is Associated with Liver Damage in Non-Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e96349.	1.1	31

#	Article	IF	CITATIONS
217	Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2023, 21, 1523-1532.e1.	2.4	31
218	1148M PNPLA3 variant and progressive liver disease: A new paradigm in hepatology. Hepatology, 2012, 56, 791-791.	3.6	30
219	Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update. Current Pharmaceutical Design, 2019, 24, 4566-4573.	0.9	30
220	Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease. World Journal of Nephrology, 2012, 1, 166.	0.8	30
221	Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease. International Journal of Environmental Research and Public Health, 2019, 16, 2755.	1.2	28
222	Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Reports, 2021, 3, 100284.	2.6	28
223	Is there an â€~ideal' diet for patients with NAFLD?. European Journal of Clinical Investigation, 2022, 52, e13659.	1.7	28
224	Iron Stores, Hepcidin, and Aortic Stiffness in Individuals with Hypertension. PLoS ONE, 2015, 10, e0134635.	1.1	28
225	CYTOTOXIC T-LYMPHOCYTE ANTIGEN-4 A49G POLYMORPHISM IS ASSOCIATED WITH SUSCEPTIBILITY TO AND SEVERITY OF ALCOHOLIC LIVER DISEASE IN ITALIAN PATIENTS. Alcohol and Alcoholism, 2004, 39, 276-280.	0.9	27
226	HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1331-1337.	2.2	27
227	Hepcidin levels in chronic hemodialysis patients: a critical evaluation. Clinical Chemistry and Laboratory Medicine, 2014, 52, 613-9.	1.4	27
228	PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. Inflammatory Bowel Diseases, 2016, 22, 134-140.	0.9	27
229	Impact of hepatitis C virus therapy on metabolism and public health. Liver International, 2017, 37, 13-18.	1.9	27
230	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2008-e2020.	1.8	27
231	What future for ribavirin?. Liver International, 2009, 29, 68-73.	1.9	26
232	Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?. Liver International, 2013, 33, 105-110.	1.9	26
233	The next wave of hepatitis C virus: The epidemic of intravenous drug use. Liver International, 2018, 38, 34-39.	1.9	26
234	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2020, 190, 2226-2236.	1.9	26

#	Article	IF	CITATIONS
235	<i>PCSK9</i> rs11591147 R46L lossâ€ofâ€function variant protects against liver damage in individuals with NAFLD. Liver International, 2021, 41, 321-332.	1.9	26
236	A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?. Cancers, 2021, 13, 1412.	1.7	26
237	Treatment of fulminant hepatic failure with intravenous prostaglandin E1. Liver Transplantation, 1998, 4, 424-431.	1.9	25
238	Mutant PNPLA3 I148M protein as pharmacological target for liver disease. Hepatology, 2017, 66, 1026-1028.	3.6	25
239	Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. Gastroenterology, 2017, 153, 1568-1580.e10.	0.6	25
240	The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis. Scientific Reports, 2017, 7, 9273.	1.6	25
241	The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology, 1999, 30, 602-605.	3.6	24
242	Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells, Molecules, and Diseases, 2005, 35, 27-32.	0.6	24
243	A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. Journal of Viral Hepatitis, 2011, 18, 628-630.	1.0	24
244	Triple therapy for <scp>HCV</scp> genotype 1 infection: telaprevir or boceprevir?. Liver International, 2012, 32, 54-60.	1.9	24
245	Hepatic steatosis and <scp>PNPLA</scp> 3 I148 <scp>M</scp> variant are associated with serum <scp>F</scp> etuinâ€ <scp>A</scp> independently of insulin resistance. European Journal of Clinical Investigation, 2014, 44, 627-633.	1.7	24
246	Cure of <scp>HCV</scp> related liver disease. Liver International, 2015, 35, 71-77.	1.9	24
247	mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients, 2019, 11, 2597.	1.7	24
248	Accuracy of imaging methods for steatohepatitis diagnosis in nonâ€alcoholic fatty liver disease patients: A systematic review. Liver International, 2019, 39, 1521-1534.	1.9	24
249	Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 73, 361-370.	1.8	24
250	Lack of genetic evidence that fatty liver disease predisposesÂtoÂCOVID-19. Journal of Hepatology, 2020, 73, 709-711.	1.8	24
251	Role of iron in hepatocellular carcinoma. Clinical Liver Disease, 2014, 3, 108-110.	1.0	23
252	Universal screening for chronic hepatitis C virus. Liver International, 2016, 36, 62-66.	1.9	22

#	Article	IF	CITATIONS
253	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. Molecular Metabolism, 2021, 53, 101275.	3.0	22
254	PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opinion on Therapeutic Targets, 2021, 25, 1033-1043.	1.5	22
255	Role and support for hepatologists at liver transplant programs in the United States. Liver Transplantation, 2008, 14, 1092-1099.	1.3	21
256	Peroxisome Proliferator-Activated Receptor Genetic Polymorphisms and Nonalcoholic Fatty Liver Disease: Any Role in Disease Susceptibility?. PPAR Research, 2013, 2013, 1-8.	1.1	21
257	The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrology, 2013, 14, 48.	0.8	20
258	<i>HFE</i> Gene Mutations and Oxidative Stress Influence Serum Ferritin, Associated with Vascular Damage, in Hemodialysis Patients. American Journal of Nephrology, 2007, 27, 101-107.	1.4	19
259	Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial. Frontiers in Neurology, 2019, 10, 755.	1.1	19
260	Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. Atherosclerosis, 2018, 268, 27-31.	0.4	19
261	Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut, 2023, 72, 381-391.	6.1	19
262	Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. Current Gastroenterology Reports, 2006, 8, 46-52.	1.1	18
263	Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. Journal of Hepatology, 2012, 56, 1209-1210.	1.8	18
264	Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood. Journal of Hepatology, 2016, 65, 668-670.	1.8	18
265	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. World Journal of Hepatology, 2018, 10, 231-245.	0.8	18
266	Management of Hepatitis C virus Genotype 2 or 3 Infection: Treatment Optimization on the Basis of Virological Response. Antiviral Therapy, 2009, 14, 143-154.	0.6	18
267	Optimizing the Current Therapy for Chronic Hepatitis C Virus: Peginterferon and Ribavirin Dosing and the Utility of Growth Factors. Clinics in Liver Disease, 2008, 12, 487-505.	1.0	17
268	Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver. Nature Communications, 2021, 12, 1822.	5.8	17
269	Modulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C. Journal of Hepatology, 2011, 55, 1470-1471.	1.8	16
270	Iron overload induces hypogonadism in male mice via extrahypothalamic mechanisms. Molecular and Cellular Endocrinology, 2017, 454, 135-145.	1.6	16

#	Article	IF	CITATIONS
271	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. Cancers, 2021, 13, 1783.	1.7	16
272	Natural history of NASH. Liver International, 2021, 41, 78-82.	1.9	16
273	Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: Effect of mono- and bi-specific somatostatin analogs on cell growth. Molecular and Cellular Endocrinology, 2014, 382, 860-870.	1.6	15
274	Proprotein convertase 7 rs236918 associated with liver fibrosis in Italian patients with <i>HFE</i> â€related hemochromatosis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1342-1348.	1.4	15
275	FGF23 and Fetuin-A Interaction in the Liver and in the Circulation. International Journal of Biological Sciences, 2018, 14, 586-598.	2.6	15
276	Comparison of three therapeutic regimens for genotypeâ€3 hepatitis C virus infection in a large realâ€life multicentre cohort. Liver International, 2020, 40, 769-777.	1.9	15
277	Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank. JHEP Reports, 2021, 3, 100262.	2.6	15
278	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Digestive and Liver Disease, 2022, 54, 154-163.	0.4	15
279	PSD3 downregulation confers protection against fatty liver disease. Nature Metabolism, 2022, 4, 60-75.	5.1	15
280	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1-16.	1.1	15
281	TNFα Promoter Polymorphisms. , 2004, 98, 047-058.		14
282	Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. Journal of Hepatology, 2013, 58, 399-401.	1.8	14
283	Current management of NAFLD/NASH. Liver International, 2021, 41, 89-94.	1.9	14
284	Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. World Journal of Gastroenterology, 2019, 25, 6094-6106.	1.4	14
285	Treatment choices for people infected with HCV. Journal of Antimicrobial Chemotherapy, 2004, 53, 708-712.	1.3	13
286	<i>HFE</i> Genotype Influences Erythropoiesis Support Requirement in Hemodialysis Patients: A Prospective Study. American Journal of Nephrology, 2008, 28, 311-316.	1.4	13
287	Genetic risk scores and personalization of care in fatty liver disease. Current Opinion in Pharmacology, 2021, 61, 6-11.	1.7	13
288	Prognostic value of copeptin and midâ€regional proadrenomedullin in COVIDâ€19â€hospitalized patients. European Journal of Clinical Investigation, 2022, 52, e13753.	1.7	13

#	Article	IF	CITATIONS
289	Hereditary hemochromatosis in a patient with congenital dyserythropoietic anemia. Blood, 2000, 96, 3653-3655.	0.6	12
290	GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. Annals of Hepatology, 2017, 16, 451-456.	0.6	12
291	Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C). Antiviral Therapy, 2019, 24, 35-44.	0.6	12
292	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. Clinical Gastroenterology and Hepatology, 2020, 18, 517-519.	2.4	12
293	Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma. Nature Communications, 2021, 12, 4878.	5.8	12
294	Trends and risk factors of <scp>SARS oV</scp> â€2 infection in asymptomatic blood donors. Transfusion, 2021, 61, 3381-3389.	0.8	12
295	Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. International Journal of Obesity, 2022, 46, 486-493.	1.6	12
296	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Digestive and Liver Disease, 2022, 54, 170-182.	0.4	12
297	Preprocedural prophylaxis with blood products in patients with cirrhosis: Results from a survey of the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2022, 54, 1520-1526.	0.4	12
298	HFEmutations in nonalcoholic fatty liver disease. Hepatology, 2008, 47, 1794-1795.	3.6	11
299	Genetic insight into COVIDâ€19â€related liver injury. Liver International, 2021, 41, 227-229.	1.9	11
300	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. EBioMedicine, 2021, 65, 103249.	2.7	11
301	Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients. Cells, 2021, 10, 611.	1.8	11
302	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Alimentary Pharmacology and Therapeutics, 2022, 55, 234-243.	1.9	11
303	Side effects of medical therapy for chronic hepatitis C. Annals of Hepatology, 2004, 3, 5-10.	0.6	11
304	1148M PNPLA3 variant and progressive liver disease: a new paradigm in hepatology. Hepatology, 2012, 56, 1883-9.	3.6	11
305	Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of <i>Ppp2r1b</i> . Science Translational Medicine, 2022, 14, eabh3831.	5.8	11
306	What is the contribution of differences in three measures of tumor necrosis factor-alpha activity to insulin resistance in healthy volunteers? Metabolism: Clinical and Experimental, 2003, 52, 1593-1596	1.5	10

#	Article	IF	CITATIONS
307	A BALANCING VIEW: We Cannot Do It Alone. American Journal of Gastroenterology, 2007, 102, 1841-1843.	0.2	10
308	Particulate matter phagocytosis induces tissue factor in differentiating macrophages. Journal of Applied Toxicology, 2016, 36, 151-160.	1.4	10
309	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158765.	1.2	10
310	Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinology, Diabetes and Metabolism, 2020, 3, e00179.	1.0	10
311	COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia. Clinical Microbiology and Infection, 2020, 26, 1576-1578.	2.8	10
312	A call to action for fatty liver disease. Liver International, 2021, 41, 1182-1185.	1.9	10
313	Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease. Current Pharmaceutical Design, 2020, 26, 998-1009.	0.9	10
314	GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. Annals of Hepatology, 2017, 16, 451-456.	0.6	10
315	Patatin-like phospholipase domain containing-3 lle148Met and fibrosis progression after liver transplantation. Hepatology, 2011, 54, 1484-1484.	3.6	9
316	104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2013, 58, S46.	1.8	9
317	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2014, 46, 18-24.	0.4	9
318	Reply. Hepatology, 2015, 62, 660-660.	3.6	9
319	AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. Digestive and Liver Disease, 2020, 52, 359-367.	0.4	9
320	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2020, 115, 1289-1292.	0.2	9
321	Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders. Journal of Clinical Medicine, 2021, 10, 423.	1.0	9
322	Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease― Journal of Hepatology, 2021, 74, 1494-1496.	1.8	9
323	Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study. Diabetes Research and Clinical Practice, 2021, 177, 108882.	1.1	9
324	Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C. PLoS ONE, 2014, 9, e106022.	1.1	9

#	Article	IF	CITATIONS
325	The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatology Communications, 2022, 6, 1213-1226.	2.0	9
326	Bloodletting Ameliorates Insulin Sensitivity and Secretion in Parallel to Reducing Liver Iron in Carriers of HFE Gene Mutations: Response to Equitani et al Diabetes Care, 2008, 31, e18-e18.	4.3	8
327	CDKN1A: A double-edged sword in fatty liver?. Cell Cycle, 2014, 13, 1371-1372.	1.3	8
328	Regulation of retinolâ€binding protein 4 and retinol metabolism in fatty liver disease. Hepatology, 2016, 64, 1414-1416.	3.6	8
329	myVCF: a desktop application for high-throughput mutations data management. Bioinformatics, 2017, 33, 3676-3678.	1.8	8
330	A novel alpha1-antitrypsin null variant (PiQ0Milano). World Journal of Hepatology, 2013, 5, 458.	0.8	8
331	Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series. Liver International, 2022, 42, 864-870.	1.9	8
332	A genetic hypothesis for burntâ€out steatohepatitis. Liver International, 2021, 41, 2816-2818.	1.9	8
333	Impact of Peginterferon Maintenance Therapy on the Risk of Developing Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus. Oncology, 2010, 78, 11-16.	0.9	7
334	14 A DRUG TRANSPORTER GENE POLYMORPHISM PREDICTS RENAL TUBULAR TOXICITY IN PATIENTS WITH CHRONIC HEPATITIS B ON LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION. Journal of Hepatology, 2010, 52, S7.	1.8	7
335	127 HOMOZYGOSITY FOR THE PNPLA3/ADIPONUTRIN 1148M POLYMORPHISM INFLUENCES LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2010, 52, S57.	1.8	7
336	Efficacy and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Renal Impairment. Journal of Clinical Pharmacology, 2011, 51, 1293-1301.	1.0	7
337	<scp>HCV</scp> F1/F2 patients: treat now or continue to wait. Liver International, 2014, 34, 79-84.	1.9	7
338	The role of interferon in the new era of hepatitis C treatments. Expert Review of Gastroenterology and Hepatology, 2014, 8, 649-656.	1.4	7
339	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. Journal of Hepatology, 2017, 66, S593.	1.8	7
340	Telomeric zinc-finger associated protein (TZAP): a new player in telomere diseases?. Annals of Translational Medicine, 2017, 5, 472-472.	0.7	7
341	Impact of natural neuromedinâ€B receptor variants on iron metabolism. American Journal of Hematology, 2020, 95, 167-177.	2.0	7
342	Prevalence and 9â€year incidence of hepatitis E virus infection among North Italian blood donors: Estimated transfusion risk. Journal of Viral Hepatitis, 2020, 27, 858-861.	1.0	7

#	Article	IF	CITATIONS
343	Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver International, 2020, 40, 22-26.	1.9	7
344	Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008â \in 2019. Liver International, 2021, , .	1.9	7
345	Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives. , 2022, 1, 57-65.		7
346	1280 DIETARY IRON OVERLOAD INDUCES VISCERAL ADIPOSE TISSUE INSULIN RESISTANCE ASSOCIATED WITH HYPER-RESISTINEMIA, AND SYNERGIZES WITH OBESITY AND FATTY LIVER IN INDUCING SYSTEMIC INSULIN RESISTANCE. Journal of Hepatology, 2011, 54, S505.	1.8	6
347	Patatin-like phospholipase domain-containing protein 3 genotype and hepatocellular carcinoma in chronic hepatitis C. Hepatology, 2011, 53, 1777-1777.	3.6	6
348	Cobalamin as a regulator of serum and cerebrospinal fluid levels of normal prions. Journal of Clinical Neuroscience, 2013, 20, 134-138.	0.8	6
349	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. Hepatology International, 2014, 8, 517-526.	1.9	6
350	The PNPLA3 I148M variant and chronic liver disease: When a genetic mutation meets nutrients. Food Research International, 2014, 63, 239-243.	2.9	6
351	Interleukin 28B Genotype and Insulin Resistance in Chronic Hepatitis C Patients. Antiviral Therapy, 2014, 19, 747-753.	0.6	6
352	Increased circulating adiponectin in males with chronic HCV hepatitis. European Journal of Internal Medicine, 2015, 26, 635-639.	1.0	6
353	Editorial: new insights into the relationship between the intestine and nonâ€alcoholic fatty liver—is "fatty gut―involved in disease progression?. Alimentary Pharmacology and Therapeutics, 2017, 46, 377-378.	1.9	6
354	Beyond fat accumulation, NAFLD genetics converges on lipid droplet biology. Journal of Lipid Research, 2019, 60, 7-8.	2.0	6
355	Uncovering the genetics of cirrhosis: New plots for the usual suspects. Liver International, 2020, 40, 281-282.	1.9	6
356	<i>NR1H4</i> rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International, 2021, 41, 2712-2719.	1.9	6
357	The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the National Digestive Diseases Advisory Board. Hepatology, 1995, 22, 1591-1597.	3.6	6
358	Retreatment of patients who do not respond to initial therapy for chronic hepatitis C Cleveland Clinic Journal of Medicine, 2004, 71, S13-S13.	0.6	6
359	Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Realâ€Life Cohort Study. Hepatology Communications, 2022, 6, 867-877.	2.0	6
360	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. Clinical and Molecular Hepatology, 2022, 28, 183-195.	4.5	6

#	Article	IF	CITATIONS
361	Management of patients with chronic hepatitis C virus infection and previous nonresponse. Reviews in Gastroenterological Disorders, 2004, 4 Suppl 1, S22-30.	0.6	6
362	The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma. Frontiers in Endocrinology, 2022, 13, 869006.	1.5	6
363	Chronic Hepatitis C. Seminars in Liver Disease, 2004, 24, 1-2.	1.8	5
364	Interferon-Free Regimens: The Near Future, the Likely and the Not So Likely. Clinics in Liver Disease, 2011, 15, 665-675.	1.0	5
365	HCV Response-Guided Therapy: Should Treatment Length Be Shortened or Extended?. Current Hepatitis Reports, 2011, 10, 4-10.	0.3	5
366	IL28B, HCV core mutations, and hepatocellular carcinoma: does host genetic make-up shape viral evolution in response to immunity?. Hepatology International, 2012, 6, 356-359.	1.9	5
367	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. Annals of Hepatology, 2014, 13, 568-571.	0.6	5
368	GNPAT p.D519G variant and iron metabolism during oral iron tolerance test. Hepatology, 2017, 65, 384-385.	3.6	5
369	Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges. Journal of Hepatology, 2019, 71, 849-850.	1.8	5
370	PS-177-HSD17B13 rs72613567 TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis. Journal of Hepatology, 2019, 70, e109-e110.	1.8	5
371	Genetic variants in the MTHFR are not associated with fatty liver disease. Liver International, 2020, 40, 1934-1940.	1.9	5
372	Clinical Determinants of Disease Progression in Patients With Beta-Sarcoglycan Gene Mutations. Frontiers in Neurology, 2021, 12, 657949.	1.1	5
373	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment. Internal and Emergency Medicine, 2022, 17, 299-302.	1.0	5
374	Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Journal of Autoimmunity, 2021, 124, 102728.	3.0	5
375	315 I148M PNPLA3 POLYMORPHISM IS ASSOCIATED WITH CLINICAL FEATURES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2012, 56, S129.	1.8	4
376	HFE mutations and iron in hemodialysis patients. Hemodialysis International, 2017, 21, S47-S57.	0.4	4
377	Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease. Metabolic Brain Disease, 2018, 33, 347-352.	1.4	4
378	Financial Compensation For Hepatologists in Different Practice Settings. Hepatology, 2019, 69, 2664-2671.	3.6	4

#	Article	IF	CITATIONS
379	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. Journal of Hepatology, 2020, 73, S13-S14.	1.8	4
380	Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology, 1994, 19, 933-940.	3.6	4
381	Genetics: A new clinical tool for the hepatologist. Liver International, 2022, 42, 724-726.	1.9	4
382	89 Risk of early atherosclerosis evaluated by carotid artery intima-media thickness in patients with non-alcoholic fatty liver disease: A case control study. Journal of Hepatology, 2006, 44, S39-S40.	1.8	3
383	Risk of severe liver disease in nonalcoholic fatty liver disease: Role of insulin resistance. Hepatology, 2008, 48, 2088-2088.	3.6	3
384	Iron genes, dysmetabolism and fibrosis in chronic hepatitis C. Journal of Hepatology, 2008, 48, 513-514.	1.8	3
385	Reply:. Hepatology, 2009, 49, 697-697.	3.6	3
386	Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations?. Internal and Emergency Medicine, 2009, 4, 91-92.	1.0	3
387	Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation. Digestive and Liver Disease, 2009, 41, e17-e20.	0.4	3
388	Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach. Translational Research, 2010, 156, 226-228.	2.2	3
389	PNPLA3 I148M polymorphism and liver damage in obese children. Journal of Pediatrics, 2011, 159, 876.	0.9	3
390	PNPLA3 lle148Met variant and hepatocellular carcinoma: A matter of fat. Digestive and Liver Disease, 2012, 44, 974-975.	0.4	3
391	Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients. BioMed Research International, 2013, 2013, 1-6.	0.9	3
392	Deciphering the Role of ω3 Fatty Acids in Nonalcoholic Steatohepatitis. Journal of Pediatric Gastroenterology and Nutrition, 2014, 59, 423-424.	0.9	3
393	My Treatment Approach to Chronic Hepatitis CÂVirus. Mayo Clinic Proceedings, 2014, 89, 934-942.	1.4	3
394	Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy. Current Hepatology Reports, 2017, 16, 169-177.	0.4	3
395	Building mass to prevent non-alcoholic fatty liver disease?. Hepatobiliary Surgery and Nutrition, 2019, 8, 173-176.	0.7	3
396	FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. Digestive and Liver Disease, 2019, 51, e26.	0.4	3

#	Article	IF	CITATIONS
397	A Balancing View: A Decision to be Shared with Patients. American Journal of Gastroenterology, 2004, 99, 975-976.	0.2	2
398	T-12 Echocardiographic epicardial fat thickness in non alcoholic fatty liver disease: A possible marker of metabolic syndrome and early vascular damage. Digestive and Liver Disease, 2011, 43, S80-S81.	0.4	2
399	Tâ€ARMSâ€PCR for the evaluation of rs12979860 IL28B genotype: an optimized protocol. Journal of Viral Hepatitis, 2012, 19, 228-228.	1.0	2
400	IL28B rs12979860 polymorphism influences serum TNFalpha levels in chronic hepatitis C. Digestive and Liver Disease, 2013, 45, 348-349.	0.4	2
401	Oxidative Stress and Hepatic Iron Overload. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 345-356.	0.4	2
402	NGM282: a step forward in the nonalcoholic steatohepatitis treatment landscape?. Hepatobiliary Surgery and Nutrition, 2018, 7, 484-486.	0.7	2
403	Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development. Journal of Hepatology, 2018, 68, S31.	1.8	2
404	Liver International: Anticipating the future of hepatology worldwide. Liver International, 2019, 39, 1796-1797.	1.9	2
405	The Natural History of NAFLD: Environmental vs. Genetic Risk Factors. , 2020, , 129-145.		2
406	Insulin resistance and tnf alpha polymorphism in Italian patients with non alcoholic fatty liver disease (NAFLD). Journal of Hepatology, 2001, 34, 235.	1.8	1
407	Correspondence. Digestive and Liver Disease, 2003, 35, 596-597.	0.4	1
408	TNFalpha promoter polymorphisms and insulin resistance in HCV-related liver disease. Journal of Hepatology, 2003, 38, 178.	1.8	1
409	Turning up the heat in the fat cell. Nature Medicine, 2004, 10, 1168-1169.	15.2	1
410	F-17 Dietary iron overload induces visceral adipose tissue insulin resistance and hyper-resistinemia, and synergizes with obesity and fatty liver in inducing systemic insulin resistance. Digestive and Liver Disease, 2011, 43, S97.	0.4	1
411	872 ADIPONECTIN IN NONALCOHOLIC FATTY LIVER DISEASE: CORRELATION WITH LIVER DAMAGE AND PNPLA3 GENOTYPE. Journal of Hepatology, 2011, 54, S347-S348.	1.8	1
412	Modulation of Iron Metabolism and Hepcidin Release by HFE Mutations in Chronic Hemodialysis Patients: Pathophysiological and Therapeutic Implications. , 0, , .		1
413	1397 ATYPICAL JUVENILE HEMOCHROMATOSIS ASSOCIATED WITH HETEROZYGOSITY FOR NOVEL HEMOJUVELIN MUTATIONS. Journal of Hepatology, 2013, 58, S561.	1.8	1
414	399 PNPLA3 I148M AFFECTS LIVER STEATOSIS IN PATIENTS WITH CHRONIC HEPATITIS B. Journal of Hepatology, 2013, 58, S164.	1.8	1

#	Article	IF	CITATIONS
415	P744 DEPDC5 GENE LOCUS ASSOCIATES WITH SEVERE LIVER FIBROSIS IN INDIVIDUALS WITH CHRONIC HCV INFECTION. Journal of Hepatology, 2014, 60, S318.	1.8	1
416	O071 : Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash. Journal of Hepatology, 2015, 62, S226.	1.8	1
417	To Be or Not to Be: The Quest for Patatin‣ike Phospholipase Domain Containing 3 p.I148M Function. Hepatology, 2021, 74, 2942-2944.	3.6	1
418	Liver Field during Immunotherapy of Hepatocellular Carcinoma: Some Like It Hot. Gastroenterology, 2021, 161, 1065-1067.	0.6	1
419	Iron and the Adipocyte: Beware the Liver!. Immuno-gastroenterology, 2012, 1, 74.	0.4	1
420	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. Annals of Hepatology, 2014, 13, 568-71.	0.6	1
421	TNF alpha and hereditary hemocromatosis: possible interactions. Journal of Hepatology, 2001, 34, 218.	1.8	0
422	Iron overload, hfe gene mutations and insulin resistance in non alcoholic fatty liver disease (NAFLD). Digestive and Liver Disease, 2002, 34, 687.	0.4	0
423	CTLA-4 recipient polymorphism influences HCV liver disease recurrence following orthotopic liver transplantation (OLT). Journal of Hepatology, 2002, 36, 43.	1.8	0
424	Cytotoxic T-lymphocyte antigen 4 is associated with development and progression of alcoholic liver disease (ALD) in Italian patients. Journal of Hepatology, 2002, 36, 66.	1.8	0
425	Iron and insulin resistance: Effect of iron manipulation on insulin receptor in HEPC2 hepatocytes. Journal of Hepatology, 2003, 38, 30-31.	1.8	0
426	63 Hepatic expression of the forkhead transcription factor foxO1 is increased in non-alcoholic steatohepatitis and associated with gluconeogenesis and insulin resistance. Journal of Hepatology, 2006, 44, S28-S29.	1.8	0
427	Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. Current Hepatitis Reports, 2006, 5, 114-120.	0.3	0
428	[100] INHERITED VARIANTS OF GENES INVOLVED IN INSULIN SIGNALING AND LIPOGENESIS INFLUENCE THE RISK OF HEPATIC FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2007, 46, S44-S45.	1.8	0
429	[378] IRON STATUS MODULATES THE EXPRESSION OF THE UBIQUITIN LIGASE MDM-2 AND ITS TARGET p53 IN MOUSE HEPATOCYTES AND HUMAN MONOCYTES; EFFECT ON THE ANTI-OXIDANT RESPONSE. Journal of Hepatology, 2007, 46, S146-S147.	1.8	0
430	[709] BASELINE ALT AND FERRITIN PREDICT HISTOLOGICAL FINDINGS IN NAFLD. Journal of Hepatology, 2007, 46, S267-S268.	1.8	0
431	[710] REVISITATION OF A COHORT OF ITALIAN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS: CHANGES IN THE LAST THREE DECADES. Journal of Hepatology, 2007, 46, S268.	1.8	0
432	[769] IRON DEPLETION BY PHLEBOTOMY IMPROVES INSULIN RESISTANCE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND HYPERFERRITINEMIA; EVIDENCE FROM A CASE CONTROL STUDY. Journal of Hepatology, 2007, 46, S288-S289.	1.8	0

#	Article	IF	CITATIONS
433	[770] ROLE OF TRB3 IN THE REGULATION OF HEPATIC LIPOGENESIS IN NONALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2007, 46, S289.	1.8	0
434	96 IRON DEPLETION BY DEFEROXAMINE UPREGULATES GLUCOSE UPTAKE AND INSULIN SIGNALING IN HEPATOCYTES AND IN A RAT MODEL OF FATTY LIVER. Journal of Hepatology, 2008, 48, S41.	1.8	0
435	702 IRON METABOLISM ALTERATIONS ASSOCIATED WITH HEPATIC IRON ACCUMULATION IN A DIETARY MODEL OF NONALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2009, 50, S257.	1.8	Ο
436	726 GENOTYPE OF THE TRANSCRIPTION FACTOR FOXO1 MEDIANTING INSULIN SIGNALING INFLUENCES THE SUSCEPTIBILITY TO AND SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE BY MODULATING FOXO1 MRNA LEVELS. Journal of Hepatology, 2009, 50, S265.	1.8	0
437	338 RISK OF EARLY ATHEROSCLEROSIS BY CAROTID ARTERY INTIMA-MEDIA THICKNESS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE AND LOW VISCERAL ADIPOSITY. Journal of Hepatology, 2010, 52, S141.	1.8	0
438	377 BETA-GLOBIN MUTATIONS ARE ASSOCIATED WITH PARENCHYMAL SIDEROSIS AND FIBROSIS SEVERITY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2010, 52, S155-S156.	1.8	0
439	OC-16 Interaction between the PNPLA3 I148M mutation and body weight in determining steatosis and the progression to cirrhosis in hereditary hemochromatosis. Digestive and Liver Disease, 2011, 43, S70.	0.4	0
440	260 ABERRANT METHYLATION OF ONCOSUPPRESSOR GENES DETECTED IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC HEPATITIS C AND HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2011, 54, S107.	1.8	0
441	903 INTERACTION BETWEEN THE PNPLA3 1148M MUTATION, BODY WEIGHT, AND STEATOSIS, IN DETERMINING THE PROGRESSION TO CIRRHOSIS IN HEREDITARY HEMOCHROMATOSIS. Journal of Hepatology, 2011, 54, S359.	1.8	0
442	136 THE A736V TMPRSS6 POLYMORPHISM IS ASSOCIATED WITH THE PENETRANCE OF HEREDITARY HEMOCHROMATOSIS AND HEPATOCELLULAR CARCINOMA IN C282Y +/+ PATIENTS. Journal of Hepatology, 2012, 56, S59.	1.8	0
443	1080 LOW RATES OF SVR TO PEGINTERFERON PLUS RIBAVIRIN IN HCV GENOTYPE 1 IL28B RS12979860 CC CIRRHOTIC PATIENTS WITHOUT RAPID VIROLOGICAL RESPONSE. Journal of Hepatology, 2012, 56, S425.	1.8	0
444	1373 EFFECT OF IRON DEPLETION ON LIVER DAMAGE IN NONALCOHOLIC FATTY LIVER DISEASE: PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL. Journal of Hepatology, 2013, 58, S552-S553.	1.8	0
445	1362 RISK OF OBSTRUCTIVE SLEEP APNEA SYNDROME AND ASSOCIATION WITH LIVER DAMAGE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE WITHOUT SEVERE OBESITY. Journal of Hepatology, 2013, 58, S547-S548.	1.8	0
446	448 IL28B GENOTYPE IS NOT ASSOCIATED WITH INSULIN RESISTANCE IN CHRONIC HEPATITIS C PATIENTS. Journal of Hepatology, 2013, 58, S183.	1.8	0
447	Reply. Hepatology, 2014, 60, 1111-1112.	3.6	0
448	Genetic Insight Into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 139-140.	0.9	0
449	P816 MERTK rs4374383 AA GENOTYPE IS ASSOCIATED WITH A LOWER PREVALENCE OF SEVERE HEPATIC STEATOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2014, 60, S342-S343.	1.8	0
450	P271 INTERACTION BETWEEN DIETARY FACTORS AND INSULIN RESISTANCE IN THE PATHOGENESIS OF NONALCOHOLIC STEATOHEPATITIS. Journal of Hepatology, 2014, 60, S155.	1.8	0

#	Article	IF	CITATIONS
451	P858 EPICARDIAL FAT THICKNESS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH MARKERS OF CARDIOVASCULAR DAMAGE AND SEVERITY OF STEATOSIS. Journal of Hepatology, 2014, 60, S358.	1.8	Ο
452	Progression of early atherosclerotic vascular damage in patients with NAFLD and in controls of general population during 10 years of follow up. Digestive and Liver Disease, 2014, 46, e26.	0.4	0
453	P817 EARLY MENOPAUSAL STATUS IS ASSOCIATED WITH THE SEVERITY OF LIVER FIBROSIS IN ITALIAN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2014, 60, S343.	1.8	0
454	Role of the receptor tyrosine kinase MER in the development of fibrosis in NAFLD. Digestive and Liver Disease, 2015, 47, e225.	0.4	0
455	P1009 : Incidence of major cardiovascular and cerebral events in patients with NAFLD and in controls of general population during 10 years of follow up: correlation between vascular and liver damage. Journal of Hepatology, 2015, 62, S725-S726.	1.8	0
456	Reply to "Statin treatment for non-alcoholic steatohepatitis― Journal of Hepatology, 2016, 64, 242-243.	1.8	0
457	Reply. Hepatology, 2016, 63, 1052-1053.	3.6	0
458	Developing a relationship with a liver transplant program. Clinical Liver Disease, 2017, 9, 73-76.	1.0	0
459	S18-1APPLYING GENETIC INFORMATION ON HEPATOCELLULAR CARCINOMA SURVEILLANCE STRATEGIES – ARE WE THERE YET?. Alcohol and Alcoholism, 2017, 52, i4-i30.	0.9	Ο
460	Postâ€transplant metabolic syndrome in children: Know better to cure better. Pediatric Transplantation, 2019, 23, e13367.	0.5	0
461	Management of Acute Hepatitis B Virus Infection. Current Hepatology Reports, 2020, 19, 276-284.	0.4	0
462	Rare <i>Atg7</i> Genetic Variants Predispose to Severe Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0
463	Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood?. Lancet Haematology,the, 2021, 8, e8-e10.	2.2	0
464	Preface. Clinics in Liver Disease, 2021, 25, xiii-xiv.	1.0	0
465	Variants APOE (rs429358) and TM6SF2 (rs187429064) confer risk to hepatocellular carcinoma. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.2	0
466	Iron overload impairs the migratory ability of a model of immature and migratory GnRH neurons. Endocrine Abstracts, 0, , .	0.0	0
467	<i>NR1H4</i> rs35724 G>C Variant Modulates Liver Damage in Nonalcoholic Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0
468	Uncovering occult hepatitis B in blood donations: a tale of two worlds. Blood Transfusion, 2019, 17, 399-400.	0.3	0